LATEST NEWS
FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
… The recent approval by the Food and Drug Administration (FDA) of ponatinib (ICLUSIG®) in…
VIDEO highlights from @montypal 2024 Annual Oncology and Research Symposium https://oncologytube.com/tag/moasc-2024-oncology-summit/ featuring presentations from @KarenReckampMD @jtmoyers @Dr_RShatsky @arafflemd Heinz-Josef Lenz @akhtari_mojtaba @DrLizBrem @UCIrvineHealth @CancerCenter @CityofHopeCME…
Check out the incredible young investigators from @cityofhope who presented their work at #MOASC24! A huge thanks to @MOASC_Office, our state society, & @oncologytube for offering them an opportunity to shine! @SalvadorjcMD @AlexisLevee @NazliDizman @NickSalgia…
Oncology Conference Videos
Oncology News
At ASH 2023, Ola Landgren, MD, Professor of Medicine and Chief Division of Myeloma at…
Al-Ola Abdallah, MD, Associate Professor of Medicine at The University of Kansas, conducted a study…
BTK Degrader BGB-16673:Phase 1 Results in B-Cell Malignancies [ASH 2023]
John F. Seymour, MBBS, Ph.D., FRACP, a clinical haematologist and the Director of the Haematology…
By. Ruth O’Regan MD Date: 12/07/2023In an interview, Ruth O’Regan MD addresses questions related to the…
Hormone Replacement Strategies in Women at Moderate to High Risk for Breast Cancer – SABCS 2023
By: Carol Fabian, MD Date. 12/07/2023 In an interview, Carol Fabian, MD, an expert in breast…
At ASH 2023, there is a discussion with Dr. Davide Matino, Assistant Professor of Medicine at…
NRG Oncology/NSABP B-51/RTOG1304 Primary Outcomes – Terry Mamounas, MD [SABCS 2023]
By. Terry Mamounas Date: 12/07/2023In a collaborative study between NVP and RT, led by oncologist…
By: Hatem Azim, MD Date. 12/08/2023At SABCS 2023, a discussion on fertility preservation and assisted reproductive…
By: Melinda Telli, MD, Date: 12/9/2023 At the SABCS 2023 conference, we had the privilege…
Teclistamab FDA Approval Biweekly Dosing Multiple Myeloma [3 KOL Interviews]
Teclistamab FDA approval biweekly dosing in Relapsed or Refractory Multiple Myeloma (3 KOL Video Interviews…
Teclistamab FDA Approval Biweekly Dosing Multiple Myeloma [3 KOL Interviews]
Teclistamab FDA approval biweekly dosing in Relapsed or Refractory Multiple Myeloma (3 KOL Video Interviews…
Sumanta (Monty) Kumar Pal, MD – Highlights and Insights from MOASC 2024 Summit: Pioneering Oncology Research and Celebrating Young Investigators
… The Medical Oncology Association of Southern California (MOASC) 2024 Summit has once again set…